Mitigating risk, realizing revenue
Whether for temporary or long-term needs, the Title Model offers an ideal solution for small to emerging biotech companies in the United States and Europe seeking an accelerated path to product launch or lacking the capital or internal resources to handle launch logistics and distribution regulations. Our experienced experts will assist you in determining the best path for your product.
Leverage our distribution capability to:
Reduce time-to-market
Ease the burden
Enable innovation
Which is right for your product?
Title Model
- Title of product transfers to ICS or Alloga while the manufacturer retains control of the pricing and customer base
- Manufacturer can leverage Alloga or ICS licenses that will remove the administrative burden from the manufacturer*
- Eliminates need for additional staff
Traditional 3PL
- Manufacturer retains ownership of product
- Additional distribution licenses are needed
- Additional workforce is needed
Regional licensing challenges that we help to solve
In Europe, Title Model solutions can be especially valuable for manufacturers who don't have their Wholesale Distribution Authorization (WDA) in place yet. The manufacturer can sell the title to Cencora and use our distribution capability to launch their product.
In the United States, Title Model allows clients to enter the US market by as much as 12 months earlier than the 3PL model. This is because many states now require manufacturers to have licenses to sell or distribute product under a 3PL model. Where a state does not have a sale restriction on manufacturers that are unlicensed or that have not registered their products with the states, ICS can launch the material in the Title Model as the manufacturer client acquires licensure in those states. Following licensure, ICS transition clients from the title environment to traditional 3PL in as little as 90 days.